Abstracts tagged "anti-TNF therapy"

Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Yoshiya Tanaka¹, Shintaro Hirata¹, Shunsuke Fukuyo¹, Masao Nawata², Satoshi Kubo², Kunihiro Yamaoka² and Kazuyoshi Saito¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴ and Mihai Bojinca¹, ¹Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…
Abstract Number: 2001 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Sarah Ringold¹, Shannon Grant², Charmaine Girdish³, Carol A. Wallace⁴ and Sean Sullivan⁵, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Axio Research LLC, Seattle, WA, ³Research, CVS Caremark, Scottsdale, AZ, ⁴Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁵Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: Medication adherence and persistence have been demonstrated to have important implications for treatment effectiveness, cost, and safety. Methotrexate is one of the most commonly…
Abstract Number: 1347 • 2012 ACR/ARHP Annual Meeting
Anti-TNFá Discontinuation in Psoriatic Arthritis: Is It Possible After Achieving Minimal Disease Activity?
Amir Haddad¹, Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission in Psoriatic Arthritis, defined as a period of at least 3 consecutive visits with no actively inflamed joints, occurs in about 17 percent…
Abstract Number: 596 • 2012 ACR/ARHP Annual Meeting
Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?
Roberta Ramonda¹, Massimo Puato², Valentina Modesti³, Mariagrazia Lorenzin⁴, Paola Frallonardo⁴, Augusta Ortolan⁴, Carla Campana³, Alessandro Lo Nigro³ and Leonardo Punzi⁵, ¹Rheumatology Unit, University of Padova, Padova, Italy, ²Department of Internal Medicine, University of Padova, Padova, Italy, ³Unit of Rheumatology, University of Padova, Padova, Italy, ⁴Rheumatology Unit, Department of Medicine, University of Padova, Padova, Italy, ⁵Clinical and Experimental Medicine, Rheumatology Unit - University of Padova, Padova, Italy
Background/Purpose: A non-invasive study focusing on the structural and functional properties of the carotid arteries was carried out in psoriatic arthritis (PsA) patients. Increased cardiovascular…
Abstract Number: 378 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting
Nicole M. Engel-Nitz¹, Sarika Ogale² and Mahesh Kulakodlu¹, ¹Observational Research, OptumInsight, Eden Prairie, MN, ²Genentech, South San Francisco, CA
Background/Purpose: Studies have shown better response for anti-TNFs (aTNF) when they are used in combination with non-biologic DMARDs (nbDMARD), than when used as monotherapies.1 Therefore,…
Abstract Number: 1923 • 2012 ACR/ARHP Annual Meeting
Biologics in Relapsing Polychondritis: A Single Center Case-Series
Guillaume Moulis¹, Laurent Sailler², Grégory Pugnet³, Leonardo Astudillo² and Philippe Arlet¹, ¹Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France
Background/Purpose: First-line treatment for relapsing polychondritis (RP) is costicosteroids (CS). Dapsone and methotrexate have been proposed as second-line therapies. Only few reports have been published…
Abstract Number: 1316 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Roy Fleischmann¹, Ronald F. van Vollenhoven², Jiri Vencovsky³, Rieke Alten⁴, Owen Davies⁵, Christian Stach⁶, Marc de Longueville⁷, Brenda Van Lunen⁸ and Ernest Choy⁹, ¹University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ²Karolinska Institute, Stockholm, Sweden, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Global Medical Affairs, UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Certolizumab pegol (CZP) has been shown to be efficacious and have an acceptable safety profile when administered every 4 weeks (Q4W) as monotherapy (FAST4WARD,…
Abstract Number: 582 • 2012 ACR/ARHP Annual Meeting
Proteomic Analysis of Synovial Tissue: A Unique Tool to Predict Response to Anti-TNF Alpha Therapy in Patients with Inflammatory Arthritis
Opeyemi S. Ademowo¹, Emily S. Collins¹, Cathy Rooney¹, A. W van Kuijk², Danielle M. Gerlag³, Paul P. Tak², Oliver FitzGerald⁴ and Stephen R. Pennington¹, ¹UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, ²Clinical Immunology / Rheumatology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Inflammatory arthritis, which includes rheumatoid arthritis (RA) and psoriatic arthritis (PsA), is a leading cause of joint deformity, disability and reduced quality of life…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
Abstract Number: 1926 • 2012 ACR/ARHP Annual Meeting
Evaluation of Strategies to Taper Anti-TNF Drugs in Patients with Inflammatory Rheumatic Disease (Rheumatoid Arthritis, Ankyloing Spondylitis, Psoriatic Arthritis, Adult-age Juvenile Idiopatic Arthritis) in Long-Term Remission
Jakub Zavada¹, Katarina Hviscova², Katerina Jarosova², Sarka Forejtova³, Jiri Stolfa², Liliana Sedova², Dana Tegzova², Jiri Vencovsky² and Karel Pavelka², ¹Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Prague, Czech Republic
Background/Purpose: While abrupt discontinuation strategies of anti-TNF drugs have been shown to result in frequent disease flares, tapering of dose may be a feasible…
Abstract Number: 1318 • 2012 ACR/ARHP Annual Meeting
Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
Vibeke Strand¹, Oana Purcaru², Ronald F. van Vollenhoven³, Ernest Choy⁴ and Roy Fleischmann⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²UCB Pharma, Brussels, Belgium, ³Karolinska Institute, Stockholm, Sweden, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Southwestern Medical Center at Dallas, University of Texas, Dallas, TX
Background/Purpose: Certolizumab pegol (CZP) monotherapy administered every 4 weeks (Q4W) for rheumatoid arthritis (RA) has been shown to be associated with rapid and sustainable improvements…
Abstract Number: 557 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On the Multiple Facets of Psoriatic Arthritis As Reported by Patients: 24 Week Patient Reported Outcome Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Dafna D. Gladman¹, Roy Fleischmann², Geoffroy Coteur³, Franz Woltering⁴ and Philip J. Mease⁵, ¹Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Monheim, Germany, ⁵Seattle Rheumatology Associates, Seattle, WA
Background/Purpose: RAPID-PsA (NCT01087788) reports efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in psoriatic arthritis (PsA).1 The effect of different imputation methodologies…
Abstract Number: 361 • 2012 ACR/ARHP Annual Meeting
Impact of Tumour Necrosis Factor Inhibitor Treatment On Hand Bone Loss in Rheumatoid Arthritis Patients Treated in Clinical Practice. Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard², Pernille Bøyesen³, Trine David Jensen⁴, Anja Thormann², Ulrik Tarp², Wolfgang Bøhme², Ditte Dencker², Hanne M. Lindegaard⁵, Uta Engling Poulsen², Annette Hansen⁶, Vibeke Stevenius Ringsdal², Annette Schlemmer⁷, Niels Graudal², Anne Rødgaard Andersen², Jakob Espesen², Gina Kollerup², Torben Grube Christensen², Randi Pelck², Bente Glintborg², Ole Rintek Madsen², Dorte Vendelbo Jensen², Ole Majgaard² and Merete L. Hetland⁸, ¹Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ⁴Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and periarticular bone loss. In RA patients with insufficient response to Disease-Modifying Anti-rheumatic drugs (DMARDs)…
Abstract Number: 1846 • 2012 ACR/ARHP Annual Meeting
Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice
Mike Russell¹, Jen Timoshanko¹, Graeme Duncan², Angela Spandley¹ and Samantha Roskell³, ¹UCB Pharma, Slough, United Kingdom, ²Healthcare at Home Ltd, Burton on Trent, United Kingdom, ³Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) therapy in the UK is standardized by the National Institute for Health and Clinical Excellence (NICE). To be eligible for anti-TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].